| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Phase 2 data readout example | Phase 2 | — | Subscribe to access the data. | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
ACADIA Pharmaceuticals Inc.$26.22
-0.24 (-0.91%)
C 56Pipeline Score Fair Value Pharma · Commercial
Market Cap
3.58 B
EPS
2.22
P/E Ratio
9.51 $
Value Trade
27.21 M
SEC Financials
Q1 2026Dilution Risk
Revenue
268.06 M
R&D Expenses
76.87 M
Operating CF
33.98 M
Total Assets
1.61 B
Total Liabilities
357.16 M
Equity
1.25 B
D/E Ratio
12,345
-3.74 %
Week
-4 %
1 Month
-12.12 %
3 Month
-8.42 %
6 Month
-4.09 %
5 Year
183.6 %
All Time
Cash Data
Cash Position
851.46 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
May 7, 2026
Overview
Volume
1.44 M
52 Week Range
19.69 - 28.35
% held by Insiders
1.28 %
% held by Institutions
96.74 %
Enterprise Value
2.78 B
Total Shares
171.26 M
Short %
8.69 %
Float Shares
126.05 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for ACADIA Pharmaceuticals Inc.
353Total events
4Upcoming
115Tier-1 (high impact)
2010 – 2026Coverage
Upcoming catalysts 4
Aug 2026
T1Topline Readout
Top-line results from Phase 2 RADIANT study of remlifanserin in Alzheimer's disease psychosis
Event history 349
Jul 6, 2026
Q3 2026
◆Topline ReadoutremlifanserinClinical Data
Top-line results from Phase 2 RADIANT study expected
Alzheimer's disease psychosissource ↗
Jun 26, 2026
▲CHMP Positive OpinionDAYBUEx-US Regulatory
CHMP positive opinion for DAYBU (Trofinetide) in EU
Rett-Syndromsource ↗
Jun 26, 2026
▲CHMP Positive OpiniontrofinetydEx-US Regulatory
CHMP positive opinion for trofinetyd in Rett syndrome
Rett syndromesource ↗
Jun 26, 2026
▲CHMP Positive OpiniontrofinetideEx-US Regulatory
CHMP positive opinion for DAYBU (trofinetide) in Rett syndrome
Rett syndromesource ↗
Jun 26, 2026
▲CHMP Positive OpiniontrofinétideEx-US Regulatory
CHMP positive opinion for DAYBU (trofinétide) in Rett syndrome
syndrome de Rettsource ↗
Jun 26, 2026
▲CHMP Positive OpinionDAYBUEx-US Regulatory
CHMP positive opinion for DAYBU (trofinetide) in EU
Rett syndromesource ↗
Jun 2026
◆Topline ReadoutACP-204Clinical Data
Topline results for RADIANT Phase 2 study of ACP-204
Alzheimer's disease psychosissource ↗
May 19, 2026
◆Oral PresentationPresentation
2026 RBC Capital Markets Global Healthcare Conference Fireside Chat
May 12, 2026
Drug Pipeline Intelligence
C56
Pipeline Score $2.3B
Pipeline ValueFair Value
Valuation Signal8
Drugs Scored2.1x
rNPV / MCap Top 84%
Small Cap (rank 147 of 911)
Percentile RankACADIA Pharmaceuticals Inc. carries a moderate pipeline score (56/100), with $3.5B risk-adjusted pipeline value, led by Pimavanserin in Neuropsychiatric Symptoms Related to Neurodegenerative Disease (Phase 3), across $109B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pimavanserin Small molecule | Neuropsychiatric Symptoms Related to Neurodegenerative Disease | Phase 3 | NCT03623321 | 50% | $1.7B | COMPLETED | 1,379 | - | - | May 5, 2023 | - | Dec 20, 2024 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
trofinetide | Rett syndrome | Phase 3 | 2022-02-28 | positive top-line results | Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results - Full year 2021 net sales grew to $484.1 million, a 10% increase over 2020 - Resubmitted sNDA for pimavanserin for the treatment of Alzh Read More | |
trofinetide | Rett syndrome | Phase 3 | 2022-02-28 | positive top-line results | Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results - Full year 2021 net sales grew to $484.1 million, a 10% increase over 2020 - Resubmitted sNDA for pimavanserin for the treatment of Alzh Read More | |
trofinetide | Rett syndrome | Phase 3 | 2022-02-28 | positive top-line results | Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results - Full year 2021 net sales grew to $484.1 million, a 10% increase over 2020 - Resubmitted sNDA for pimavanserin for the treatment of Alzh Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ACAD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ACAD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ACADAcadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
Acadia Pharmaceuticals has appointed Carl Segerstrom as the new Chief People Officer. This leadership change aims to enhance the company's human resources strategy. The appointment reflects Acadia's commitment to fostering a strong organizational culture.
Read more →ACADDAYBU® (trofinetyd) zalecany w UE przez CHMP do stosowania w leczeniu zespołu Retta
The CHMP has recommended DAYBU® (trofinetyd) for use in the treatment of Rett syndrome in the EU. This recommendation marks a significant step forward in providing therapeutic options for patients suffering from this condition. The endorsement from the CHMP highlights the potential benefits of trofinetyd in managing Rett syndrome.
Read more →ACADDAYBU® (Trofinetide) vom CHMP für die Zulassung in der Europäischen Union empfohlen
The article discusses the recommendation by the CHMP for the approval of DAYBU® (Trofinetide) in the European Union. However, no specific details or implications regarding this recommendation are provided in the text.
Read more →ACADDAYBU® (trofinétide) recommandé dans l’UE par le CHMP pour le traitement du syndrome de Rett
The CHMP has recommended DAYBU® (trofinétide) for the treatment of Rett syndrome in the EU. This recommendation marks a significant advancement in addressing the needs of patients suffering from this rare neurological disorder. If approved, it could lead to improved treatment options for affected individuals.
Read more →ACADDAYBU® (trofinetide) in de EU aanbevolen door CHMP voor de behandeling van het Rett-syndroom
The CHMP has recommended DAYBU® (trofinetide) for the treatment of Rett syndrome in the EU. This recommendation is a significant step towards potential approval, but further details on the implications and next steps are not provided.
Read more →ACAD▲ +6.7%on this newsshared move
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of DAYBU® (trofinetide) in the European Union. This recommendation marks a crucial advancement for the drug, which is aimed at addressing specific medical needs. The decision is now pending final approval from the European Commission.
Read more →ACADAcadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
Acadia Pharmaceuticals has released its financial results for the first quarter of 2026, reaffirming its financial guidance for the year. The report indicates the company's ongoing commitment to its financial targets despite the current market conditions. Further details on revenue and expenditures were not disclosed in the article.
Read more →ACADAcadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
Acadia Pharmaceuticals announced the planned retirement of Dr. Elizabeth H.Z. Thompson, Head of Research and Development, for personal reasons. She will remain in her role until a successor is appointed and will continue as a consultant through at least 2026. Acadia is actively searching for a new R&D leader while maintaining its clinical development programs.
Read more →ACADAcadia Pharmaceuticals to Participate at Upcoming May 2026 Investor Conferences
Acadia Pharmaceuticals has announced its participation in two upcoming investor conferences in May 2026. The first is the BofA Securities 2026 Health Care Conference, and the second is the RBC Capital Markets Global Healthcare Conference. Live webcasts of the events will be available on the company's website, ensuring accessibility for investors.
Read more →ACADAcadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Acadia Pharmaceuticals Inc. will participate in two upcoming investor conferences, including the BofA Securities 2026 Health Care Conference and the RBC Capital Markets Global Healthcare Conference. The presentations will be available via live webcasts on the company's website. Acadia focuses on developing treatments for neurological and rare diseases, with a strong pipeline of programs.
Read more →ACADAcadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
Acadia Pharmaceuticals is set to present data at the upcoming 2026 American Academy of Neurology Annual Meeting. The details regarding the specific data to be presented are currently unspecified. This event is significant for the company as it showcases their ongoing research efforts in neurology.
Read more →ACADAcadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
Acadia Pharmaceuticals has announced it will report its first quarter 2026 financial results on May 6, 2026, after the U.S. markets close. The company will also host a conference call and webcast at 4:30 p.m. Eastern Time on the same day. This event will be accessible via Acadia's website and will be archived for later access.
Read more →ACADAcadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
Acadia Pharmaceuticals has announced that DAYBUE® STIX (trofinetide) is now broadly available in the United States for the treatment of Rett Syndrome. This development marks a significant milestone in providing patients with access to a new therapeutic option. The availability of this treatment aims to improve the quality of life for those affected by this rare neurological disorder.
Read more →ACADAcadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
Acadia Pharmaceuticals will participate in a fireside chat at the Stifel 2026 Virtual CNS Forum on March 17, 2026. The event will be accessible via a live webcast on Acadia's website, with an archived recording available for one month post-event. Acadia continues to focus on innovative treatments for neurological and rare diseases.
Read more →ACADAcadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
Acadia Pharmaceuticals has appointed Jonathan M. Poole to its Board of Directors, effective March 3, 2026. Poole, who has extensive experience in biopharmaceutical finance, will also serve on the Audit Committee. His appointment is seen as a strategic move to bolster the company's financial and operational expertise during a critical growth phase.
Read more →ACADAcadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
Acadia Pharmaceuticals announced a negative opinion from the CHMP regarding trofinetide for Rett syndrome. Despite the pivotal trial meeting its endpoints, the CHMP cited limitations in treatment effect and symptom capture. Acadia plans to request a re-examination, highlighting community support for the treatment's potential benefits.
Read more →ACADAcadia Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operating Overview
Acadia Pharmaceuticals reported strong financial results for Q4 and full year 2025, with total revenues of $284 million for the quarter and $1.07 billion for the year. The company highlighted significant growth in NUPLAZID and DAYBUE sales, with guidance for 2026 projecting revenues between $1.22 billion and $1.28 billion. CEO Catherine Owen Adams emphasized the company's strong commercial performance and the potential of their R&D pipeline, including an important Phase 2 study in Alzheimer's disease psychosis.
Read more →ACADAcadia Pharmaceuticals to Participate at Upcoming March 2026 Investor Conferences
Acadia Pharmaceuticals Inc. has announced its participation in three upcoming investor conferences in March 2026. The events include the TD Cowen's 46th Annual Health Care Conference and The Citizens Life Sciences Conference, where the company will host fireside chats. Live webcasts will be available on their website, showcasing their commitment to investor engagement.
Read more →ACADAcadia Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Acadia Pharmaceuticals Inc. will announce its fourth quarter and full year 2025 financial results on February 25, 2026. The announcement will be followed by a conference call and webcast at 4:30 p.m. Eastern Time. The call will be accessible on the company's website and archived for later viewing.
Read more →ACAD▼ -5.2%on this newsshared move
Acadia Pharmaceuticals Provides Update on Regulatory Submission for Trofinetide for the Treatment of Rett Syndrome in the European Union
Acadia Pharmaceuticals announced a negative trend vote from the CHMP regarding its Marketing Authorization Application for trofinetide, intended for treating Rett syndrome in the EU. The company plans to request a re-examination of this opinion after the formal adoption. Despite the setback, Acadia emphasizes the strong supporting data and its commitment to the Rett syndrome community.
Read more →ACADAcadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
Acadia Pharmaceuticals provided updates on its business and pipeline during the J.P. Morgan Healthcare Conference. The company projects combined net sales of $1.7 billion by 2028, with significant contributions from NUPLAZID and DAYBUE. Key milestones include the upcoming Phase 2 results for remlifanserin and the limited launch of DAYBUE STIX in early 2026.
Read more →ACADAcadia Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operating Overview - Third quarter total revenues of $278.6 million, up 11% year-over-year - Narrowing and raising high end of NUPLAZID net product
Acadia Pharmaceuticals reported a robust third quarter performance with total revenues of $278.6 million, marking an 11% increase from the previous year. The company saw strong sales for its products, NUPLAZID and DAYBUE, driving a net income of $71.8 million. Acadia has raised its guidance for both product lines, expecting continued growth in sales for 2025. However, rising research and development expenditures could pose challenges to long-term profitability.
Read more →ACADAcadia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operating Overview - Second quarter total revenues of $264.6 million, up 9% year-over-year - Second quarter NUPLAZID (pimavanserin) net product sal
Acadia Pharmaceuticals reported a robust financial performance for the second quarter of 2025, with total revenues reaching $264.6 million, reflecting a 9% increase year-over-year. NUPLAZID and DAYBUE net product sales also grew, by 7% and 14% respectively. The company raised the low end of its guidance for NUPLAZID sales to between $665 and $690 million. Additionally, positive developments in their research pipeline and successful patent litigation for NUPLAZID bolster their market position, despite a decrease in net income due to higher tax obligations.
Read more →ACADAcadia Pharmaceuticals Reports First Quarter 2025 Financial Results and Operating Overview - First quarter total revenues of $244.3 million, up 19% year-over-year - First quarter NUPLAZID (pimavanserin) net product sales
Acadia Pharmaceuticals has reported strong financial results for the first quarter of 2025, with total revenues reaching $244.3 million, a 19% increase compared to the previous year. NUPLAZID net product sales grew by 23% to $159.7 million while DAYBUE sales increased by 11% to $84.6 million. The company also announced an accelerated timeline for its COMPASS PWS Phase 3 study of ACP-101, expecting topline results in early Q4 2025. Acadia reiterated its full year 2025 revenue guidance, maintaining a positive outlook for their ongoing growth and strategic initiatives.
Read more →ACADAcadia Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview - 2024 total net product sales of $957.8 million, reflecting 32% revenue growth - Fourth quarter DAYBUE (trofineti
Acadia Pharmaceuticals reported robust financial results for the fourth quarter and the full year of 2024, achieving total net product sales of $957.8 million, a 32% increase from the previous year. The company's ambitious guidance for 2025 ranges from $1.03 billion to $1.095 billion in total revenues. Both NUPLAZID and DAYBUE are expected to contribute significantly to forthcoming growth, with estimates for their respective net sales set between $650-690 million and $380-405 million. Acadia also highlighted advancements in its clinical pipeline and ongoing efforts to expand its market presence.
Read more →ACAD▲ +5.3%on this news· ran to +22% by day 3
Acadia Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operating Overview - 3Q24 total revenues of $250.4 million, up 18% year-over-year - 3Q24 NUPLAZID (pimavanserin) net product sales of $159.2 million
Acadia Pharmaceuticals reported a successful third quarter in 2024, with total revenues of $250.4 million, an 18% increase from the previous year. Sales of NUPLAZID and DAYBUE grew, contributing to a notable net income of $32.8 million compared to a net loss last year. The company received marketing authorization for DAYBUE in Canada for treating Rett syndrome, and its CEO expressed optimism about future growth. However, increased selling and administrative costs were noted, highlighting potential financial challenges ahead.
Read more →ACADAcadia Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operating Overview - Second quarter total net product sales of $242.0 million, up 46% year-over-year
Acadia Pharmaceuticals reported its second quarter financial results for 2024, achieving total net product sales of $242 million, a significant 46% increase from the previous year. Key drivers of this growth include steady sales from NUPLAZID and DAYBUE, alongside ongoing advancements in clinical trials for Prader-Willi syndrome and Alzheimer's disease psychosis. Despite a decrease in DAYBUE's sales guidance, Acadia's cash reserves have grown, reflecting its solid financial position. The company is managing rising R&D and operational costs as it continues to enhance its product offerings.
Read more →ACADAcadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview - First quarter NUPLAZID (pimavanserin) net product sales of $129.9 million - First quarter DAYBUE (trofinetide) net product sale
Acadia Pharmaceuticals reported strong financial results for the first quarter of 2024, with total net product sales of $205.8 million, marking a 74% increase from the previous year. The growth was driven primarily by the addition of its new product, DAYBUE, and increased sales of NUPLAZID. The company provided reaffirmed guidance for both NUPLAZID and DAYBUE sales for the full year while reporting a net income of $16.6 million. Additionally, Acadia continues to advance its clinical trials for various indications and appointed a new executive vice president for research and development.
Read more →ACADAcadia Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operating Overview - 2023 total net product sales of $726.4 million, reflecting 40% revenue growth. - Fourth quarter DAYBUE (trofinet
Acadia Pharmaceuticals reported strong financial results for the fourth quarter and full year 2023, with total net product sales reaching $726.4 million, driven by a 40% revenue growth. The launch of DAYBUE for Rett syndrome significantly contributed to this growth, alongside a steady rise in NUPLAZID sales. Acadia's pipeline also advanced with the initiation of pivotal trials for ACP-101 and ACP-204. The company's financial future looks promising as it set ambitious sales expectations for both DAYBUE and NUPLAZID for 2024.
Read more →ACADAcadia Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operating Overview - Company reports record revenues resulting from strong DAYBUE launch and growth in NUPLAZID franchise - 3Q23 DAYBUE (trofinetide
Acadia Pharmaceuticals reported strong financial results for Q3 2023, with record revenues of $211.7 million driven by the successful launch of DAYBUE for Rett syndrome and growth in the NUPLAZID franchise. The company's net product sales of DAYBUE were $66.9 million, while NUPLAZID reached $144.8 million. Despite the impressive revenue figures, Acadia recorded a net loss of $65.2 million for the quarter, an increase from the previous year, driven by rising operational costs. Looking ahead, the company is set to initiate new clinical studies to expand its pipeline further.
Read more →ACADAcadia Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operating Overview - 2Q23 DAYBUE (trofinetide) net product sales of $23.2 million - 2Q23 NUPLAZID (pimavanserin) net product sales of $142.0 millio
Acadia Pharmaceuticals reported robust financial results for Q2 2023, showcasing significant sales from its products DAYBUE and NUPLAZID. DAYBUE achieved sales of $23.2 million in its first quarter, indicating solid market demand. NUPLAZID saw a healthy increase to $142 million in sales. The company is actively advancing its pipeline, having completed enrollment in critical clinical trials, including those for schizophrenia and Prader-Willi syndrome, while expanding its licensing agreements.
Read more →ACADAcadia Pharmaceuticals Acquires Ex-North American Rights to Trofinetide and Global Rights to Neuren s NNZ-2591 in Rett Syndrome and Fragile X Syndrome Expanded agreement follows Acadia s April 2023 U.S. launch of DAYBUE
Acadia Pharmaceuticals has expanded its licensing agreement with Neuren Pharmaceuticals to acquire ex-North American rights for the drug trofinetide and global rights for NNZ-2591, both targeting Rett syndrome and Fragile X syndrome. In April 2023, Acadia launched trofinetide, known as DAYBUE, which is the first drug approved for treating Rett syndrome. The agreement enables Acadia to broaden access to these treatments globally while receiving an upfront payment of $100 million and potential future earnings tied to sales milestones. This strategic move enhances Acadia's rare disease business and aligns with the company's corporate goals.
Read more →ACADAcadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview - 1Q23 NUPLAZID net sales of $118.5 million - Announced the U.S. FDA Approval of DAYBUE (trofinetide) for the Treatment of Rett S
Acadia Pharmaceuticals has reported its financial results for Q1 2023, highlighting net sales of $118.5 million for NUPLAZID and the FDA approval of DAYBUE for Rett syndrome. The launch of DAYBUE marks a significant advancement as it is the first approved treatment for this condition. While the company faced a net loss of $43 million, it showed improvement compared to the previous year and continues to invest in its pipeline, with important studies ongoing. Acadia reaffirms its financial guidance for the year ahead.
Read more →ACAD▲ +6.6%on this news
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operating Overview - Full year 2022 net sales of $517.2 million, an increase of 7% over 2021 - Prescription Drug User Fee Act (PDUFA)
Acadia Pharmaceuticals disclosed its financial performance for the fourth quarter and full year of 2022, reporting net sales of $517.2 million, a 7% rise from the previous year. The company anticipates significant developments in 2023, highlighted by a PDUFA action date for trofinetide for Rett syndrome set for March 12. Despite a notable increase in sales, Acadia faced net losses during the year, along with a decrease in cash reserves compared to the previous year. The company remains focused on advancing its drug development pipeline and maintaining profitability.
Read more →ACADAcadia Pharmaceuticals Reports Third Quarter 2022 Financial Results - 3Q22 net sales of $130.7 million - Prescription Drug User Fee Act action date set for
Acadia Pharmaceuticals Reports Third Quarter 2022 Financial Results - 3Q22 net sales of $130.7 million - Prescription Drug User Fee Act action date set for March 12, 2023 for trofinetide for the treatment of Rett syndrome SAN DIEGO, CA, November 2, 2022 Acadia Pharmaceutical
Read more →ACADAcadia Pharmaceuticals Reports Second Quarter 2022 Financial Results - 2Q22 net sales of $134.6 million, a 17% increase over 2Q21 - NDA submitted for trofinetide for the treatment of Rett syndrome
Acadia Pharmaceuticals Reports Second Quarter 2022 Financial Results - 2Q22 net sales of $134.6 million, a 17% increase over 2Q21 - NDA submitted for trofinetide for the treatment of Rett syndrome SAN DIEGO, CA, August 8, 2022 Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today
Read more →ACADAcadia Pharmaceuticals Reports First Quarter 2022 Financial Results - 1Q22 net sales of $115.5 million, an 8% increase over 1Q21 - Reiterating FY22 net sales guidance of $510 to $560 million - FDA Advisory Committee meet
Acadia Pharmaceuticals Reports First Quarter 2022 Financial Results - 1Q22 net sales of $115.5 million, an 8% increase over 1Q21 - Reiterating FY22 net sales guidance of $510 to $560 million - FDA Advisory Committee meeting to review sNDA for pimavanserin for the treatment o
Read more →ACADAcadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results - Full year 2021 net sales grew to $484.1 million, a 10% increase over 2020 - Resubmitted sNDA for pimavanserin for the treatment of Alzh
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results - Full year 2021 net sales grew to $484.1 million, a 10% increase over 2020 - Resubmitted sNDA for pimavanserin for the treatment of Alzheimer's disease psychosis - Delivered positive top-line
Read more →ACAD▲ +5.2%on this news· ran to -17% by day 1
Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID (pimavanserin) - Acadia plans to resubmit its sNDA in the first quarter of 2022 - Conference call
Acadia Pharmaceuticals Announces Plan for a Resubmission of its Supplemental New Drug Application to U.S. FDA for NUPLAZID (pimavanserin) - Acadia plans to resubmit its sNDA in the first quarter of 2022 - Conference call and webcast to be held today at 4:30 p.m. Eastern Time
Read more →ACADAcadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer SAN DIEGO ( BUSINESS WIR E ) Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the promotion of Ma
Acadia Pharmaceuticals Announces Promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer DIEGO (BUSINESS WIRE) Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the promotion of Mark Schneyer to Executive Vice President, Chief Financial Officer
Read more →ACADAcadia Pharmaceuticals Announces Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome - Trofinetide met co-primary efficacy endpoints demonstrating statistically significant i
Acadia Pharmaceuticals Announces Positive Top-line Results from Lavender Trial of Trofinetide in Rett Syndrome - Trofinetide met co-primary efficacy endpoints demonstrating statistically significant improvement over placebo in the Rett Syndrome Behaviour Questionnaire (RSBQ) (
Read more →ACADAcadia Pharmaceuticals Reports Third Quarter 2021 Financial Results - 3Q21 net sales of $131.6 million, a 9% increase over 3Q20 - FDA meeting scheduled to discuss next steps towards a resubmission of the pimavanserin sND
Acadia Pharmaceuticals Reports Third Quarter 2021 Financial Results - 3Q21 net sales of $131.6 million, a 9% increase over 3Q20 - FDA meeting scheduled to discuss next steps towards a resubmission of the pimavanserin sNDA SAN DIEGO, CA, November 8, 2021 - Acadia Pharmaceutica
Read more →ACADAcadia Pharmaceuticals Reports Second Quarter 2021 Financial Results - 2Q21 net sales of $115.2 million, a 5% increase over 2Q20 - Fiscal year 2021 revenue guidance reduced to $480 to $515 million - Type A meeting held w
Acadia Pharmaceuticals Reports Second Quarter 2021 Financial Results - 2Q21 net sales of $115.2 million, a 5% increase over 2Q20 - Fiscal year 2021 revenue guidance reduced to $480 to $515 million - Type A meeting held with FDA regarding DRP; Acadia will continue discussion w
Read more →ACADAcadia Pharmaceuticals Reports First Quarter 2021 Financial Results - 1Q21 net sales of $106.6 million, an 18% increase over 1Q20 - Reiterating FY21 net sales guidance of $510 to $550 million
Acadia Pharmaceuticals Reports First Quarter 2021 Financial Results - 1Q21 net sales of $106.6 million, an 18% increase over 1Q20 - Reiterating FY21 net sales guidance of $510 to $550 million SAN DIEGO, CA, May 5, 2021 - Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today annou
Read more →ACADAcadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis -
Acadia Pharmaceuticals Receives Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis - Conference call and webcast to be held today at 8:00 a.m
Read more →ACADAcadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis - Conference call and w
Acadia Pharmaceuticals Provides Regulatory Update on Supplemental New Drug Application for Pimavanserin for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis - Conference call and webcast to be held today at 5:00 p.m. Eastern Time SAN DI
Read more →ACADAcadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results - Full year 2020 net sales grew to $441.8 million, a 30% increase over 2019 - Upcoming PDUFA action date of
Acadia Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results - Full year 2020 net sales grew to $441.8 million, a 30% increase over 2019 - Upcoming PDUFA action date of April 3, 2021 for supplemental New Drug Application for pimavanserin for the treatment
Read more →ACADAcadia Pharmaceuticals Reports Third Quarter 2020 Financial Results - 3Q20 Net Sales of $120.6 Million, a 27% Increase Over 3Q19
Acadia Pharmaceuticals Reports Third Quarter 2020 Financial Results - 3Q20 Net Sales of $120.6 Million, a 27% Increase Over 3Q19 SAN DIEGO, CA, November 4, 2020 - Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commerciali
Read more →ACADACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio - First-in-class, non-opioid, mechanism interrupts pain pathways - Phase 2 initiation planned for the first half of 2021 SAN DIEGO
ACADIA Pharmaceuticals Acquires CerSci Therapeutics, Adds Novel Pain Program to Portfolio non-opioid, mechanism interrupts pain pathways - Phase 2 initiation planned for the first SAN DIEGO, CA, and FORT WORTH, TX - Aug 25, 2020 ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today
Read more →ACADACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results - 2Q20 Net Sales of $110.1 Million, a 32% Increase Over 2Q19 - FDA filed the supplemental NDA for pimavanserin for the treatment of dementia-related ps
ACADIA Pharmaceuticals Reports Second Quarter 2020 Financial Results - 2Q20 Net Sales of $110.1 Million, a 32% Increase Over 2Q19 - FDA filed the supplemental NDA for pimavanserin for the treatment of dementia-related psychosis with a PDUFA action date set for April 3, 2021
Read more →ACADACADIA Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis - If approved,
ACADIA Announces U.S. FDA Accepted for Filing the Supplemental New Drug Application for NUPLAZID (pimavanserin) for the Treatment of Hallucinations and Delusions Associated with Dementia-Related Psychosis - If approved, NUPLAZID would be the first and only treatment indicated
Read more →ACADACADIA PHARMACEUTICALS INC. 2004 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS ON FEBRUARY 25, 2004 APPROVED BY STOCKHOLDERS ON MAY 5, 2004 AMENDED BY THE BOARD OF DIRECTORS ON APRIL 29, 2016 APPROVED BY
ACADIA PHARMACEUTICALS INC. 2004 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS ON FEBRUARY 25, 2004 APPROVED BY STOCKHOLDERS ON MAY 5, 2004 AMENDED BY THE BOARD OF DIRECTORS ON APRIL 29, 2016 STOCKHOLDERS ON JUNE 10, 2016 AMENDED BY THE BOARD OF DIRECTORS:
Read more →ACADACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results - 1Q20 Net Sales of $90.1 Million, a 43% Increase Over 1Q19 - On-track to submit supplemental NDA for pimavanserin for the treatment of dementia-related
ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results - 1Q20 Net Sales of $90.1 Million, a 43% Increase Over 1Q19 - On-track to submit supplemental NDA for pimavanserin for the treatment of dementia-related psychosis (DRP) this summer - Announced worldwide licen
Read more →ACADACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results - Full Year 2019 Net Sales Grew to $339.1 Million, a 52% Increase over Full Year 2018 - 2020 Net Sales Guidance of $440 to $470 Million -
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results - Full Year 2019 Net Sales Grew to $339.1 Million, a 52% Increase over Full Year 2018 - 2020 Net Sales Guidance of $440 to $470 Million - On-Track to Submit Supplemental New Drug Application fo
Read more →ACADForward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors which may cause our actual re
Steve Davis, CEO 38th Annual J.P. Morgan Healthcare Conference January 14, 2020 Exhibit 99.1 Forward-Looking Statement This presentation contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other f
Read more →ACADACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results - 3Q19 Net Sales Grew to $94.6 Million, a 62% Increase Over 3Q18 - 2019 Net Sales Guidance Increased to $330 to $340 Million - Initiated Phase 3 LAVENDE
ACADIA Pharmaceuticals Reports Third Quarter 2019 Financial Results - 3Q19 Net Sales Grew to $94.6 Million, a 62% Increase Over 3Q18 - 2019 Net Sales Guidance Increased to $330 to $340 Million - Initiated Phase 3 LAVENDER Study of Trofinetide in Rett Syndrome, a Rare Neurode
Read more →ACADACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock
ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock SAN DIEGO, CA, September 17, 2019 ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical
Read more →ACADACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis - Pimavanserin achieved robust sta
ACADIA Pharmaceuticals Announces Pivotal Phase 3 HARMONY Trial Stopped Early for Positive Efficacy as Pimavanserin Meets the Primary Endpoint in Patients with Dementia-Related Psychosis - Pimavanserin achieved robust statistical superiority over placebo in time to relapse of d
Read more →ACADACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results - 2Q19 Net Sales Grew to $83.2 Million, a 46% Increase Over 2Q18 - 2019 Net Sales Guidance Increased to $320 Million to $330 Million
ACADIA Pharmaceuticals Reports Second Quarter 2019 Financial Results - 2Q19 Net Sales Grew to $83.2 Million, a 46% Increase Over 2Q18 - 2019 Net Sales Guidance Increased to $320 Million to $330 Million SAN DIEGO, CA, July 31, 2019 - ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD),
Read more →ACADACADIA P HARMACEUTICALS I NC . 2010 E QUITY I NCENTIVE P LAN A DOPTED BY THE B OARD OF D IRECTORS : M ARCH 12, 2010 A PPROVED BY THE S TOCKHOLDERS : J UNE 11, 2010 A MENDED BY THE B OARD OF D IRECTORS : A PRIL 17, 2013 A
ACADIA PHARMACEUTICALS INC. 2010 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: APPROVED BY THE STOCKHOLDERS: AMENDED BY THE BOARD OF DIRECTORS: APRIL 17, 2013 STOCKHOLDERS: JUNE 7, 2013 BOARD OF DIRECTORS: APRIL 17, 2015 BY THE STOCKHOLDERS: JUNE 15, 2015 BY T
Read more →ACADACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results - 1Q19 Net Sales Grew to $63.0 Million, a 29% Increase Over 1Q18 - Updated 2019 Net Sales Guidance to $280 Million to $300 Million - Completed Enrollmen
ACADIA Pharmaceuticals Reports First Quarter 2019 Financial Results - 1Q19 Net Sales Grew to $63.0 Million, a 29% Increase Over 1Q18 - Updated 2019 Net Sales Guidance to $280 Million to $300 Million - Completed Enrollment in Two Late-Stage Adjunctive Schizophrenia Studies wit
Read more →ACADACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results - Fourth Quarter 2018 Net Sales Grew to $59.6 Million, a 37% Increase Over 4Q17 - Full Year 2018 Net Sales Grew to $223.8 Million, a 79%
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results - Fourth Quarter 2018 Net Sales Grew to $59.6 Million, a 37% Increase Over 4Q17 - Full Year 2018 Net Sales Grew to $223.8 Million, a 79% Increase Over Full Year 2017 - Late Stage Pipeline Progr
Read more →ACADACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results -Third Quarter Net Sales Grew to $58.3 Million -Recently Announced Positive Top-line Results from the Phase 2 CLARITY Trial of Pimavanserin for Adjuncti
ACADIA Pharmaceuticals Reports Third Quarter 2018 Financial Results -Third Quarter Net Sales Grew to $58.3 Million -Recently Announced Positive Top-line Results from the Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment for Major Depressive Disorder -FDA Issued S
Read more →ACADACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD) - Pimavanserin met primary endpoint with sta
ACADIA Pharmaceuticals Announces Positive Top-line Results from Phase 2 CLARITY Trial of Pimavanserin for Adjunctive Treatment in Patients with Major Depressive Disorder (MDD) primary endpoint with statistically significant overall improvement in HAMD-17 total score compared to
Read more →ACADACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results -Second Quarter Net Sales Grew to $57.1 Million, Representing a 17% Sequential Increase Over 1Q18 and 87% Increase Over 2Q17 -Announced FDA Approval of
ACADIA Pharmaceuticals Reports Second Quarter 2018 Financial Results -Second Quarter Net Sales Grew to $57.1 Million, Representing a 17% Sequential Increase Over 1Q18 and 87% Increase Over 2Q17 -Announced FDA Approval of New Dosing Formulation and Strength of NUPLAZID (Pimavan
Read more →ACADACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results -Strong Performance for NUPLAZID in First Quarter 2018 -First Quarter Net Sales Grew to $48.9 Million, Representing a 12% Sequential Increase Over 4Q17
ACADIA Pharmaceuticals Reports First Quarter 2018 Financial Results -Strong Performance for NUPLAZID in First Quarter 2018 -First Quarter Net Sales Grew to $48.9 Million, Representing a 12% Sequential Increase Over 4Q17 and 220% Increase Over 1Q17 -ACADIA Reiterates 2018 Net
Read more →ACADBlueprint ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results -Fourth Quarter and Full Year 2017 Net Sales Grew to $43.6 Million and $124.9 Million, Respectively
ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2017 -Fourth Quarter and Full Year 2017 Net Sales Grew to $43.6 Million and $124.9 Million, Respectively SAN DIEGO, CA, February 27, 2018 ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focu
Read more →ACADACADIA Pharmaceuticals Reports Third Quarter 2017 Financial Results -Third Quarter Net Sales Grew to $35.6 Million -Company Raises Annual 2017 Net Sales Guidance to Between $124 Million and $127 Million
Pharmaceuticals Reports Third Quarter 2017 Financial Net Sales Grew to $35.6 Million Annual 2017 Net Sales Guidance to Between $124 Million and $127 SAN DIEGO, CA, November 7, 2017 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the develo
Read more →ACADACADIA Pharmaceuticals Reports Second Quarter 2017 Financial Results Second Quarter Net Sales Grew to $30.5 Million Including $3.6 Million From Transition to Sell-In Method of Accounting
ACADIA Pharmaceuticals Reports Second Quarter 2017 Financial Results Second Quarter Net Sales Grew to $30.5 Million Including $3.6 Million From Transition to Sell-In Method of SAN DIEGO, CA, August 8, 2017 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical compa
Read more →ACADBlueprint ACADIA Pharmaceuticals Reports First Quarter 2017 Financial Results
ACADIA Pharmaceuticals Reports First Quarter 2017 Financial Results SAN DIEGO, CA May 9, 2017 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in ce
Read more →ACADBlueprint ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended
ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2016 NUPLAZID Net Product Sales Grew to $12.0 Million in Fourth Quarter 2016 Executing on Broad Clinical Development Program in Alzheimer's Disease Psychosis, Alzheimer's Dise
Read more →ACADSecconnect.com ACADIA Pharmaceuticals Announces Positive Top-Line Results From Phase II Study of Pimavanserin for Alzheimer ' s Disease Psychosis Data Support Moving Forward With Further Development in Alzheimer ' s Dise
ACADIA Pharmaceuticals Announces Positive Top-Line Results From Phase II Study of Pimavanserin for Alzheimer's Disease Psychosis Data Support Moving Forward With Further Development in Alzheimer's Disease Psychosis Conference Call and Webcast to Be Held Today, December 20, 2016
Read more →ACADACADIA Pharmaceuticals Reports Third Quarter 2016 Financial Results NUPLAZID Net Product Sales Grew to $5.3 Million in the First Full Quarter of Commercialization Expanding Pimavanserin Clinical Program With Initiation o
ACADIA Pharmaceuticals Reports Third Quarter 2016 Financial Results NUPLAZID Net Product Sales Grew to $5.3 Million in the First Full Quarter of Commercialization Expanding Pimavanserin Clinical Program With Initiation of Studies for Alzheimer's Disease Agitation and Adjunctiv
Read more →ACADACADIA Pharmaceuticals Reports Second Quarter 2016 Financial Results Quarter highlighted by approval and launch of NUPLAZID (pimavanserin) in the United States, the first and only FDA-approved drug for the treatment of h
ACADIA Pharmaceuticals Reports Second Quarter 2016 Financial Results Quarter highlighted by approval and launch of NUPLAZID (pimavanserin) in the United States, the first and only FDA-approved drug for the treatment of hallucinations and delusions associated with Parkinson's di
Read more →ACADACADIA P HARMACEUTICALS I NC. 2004 E MPLOYEE S TOCK P URCHASE P LAN A DOPTED BY THE B OARD OF D IRECTORS ON F EBRUARY 25, 2004 A PPROVED BY STOCKHOLDERS ON M AY 5, 2004 A MENDED BY THE B OARD OF D IRECTORS ON A PRIL 29,
ACADIA PHARMACEUTICALS INC. EMPLOYEE STOCK PURCHASE PLAN BOARD OF DIRECTORS ON FEBRUARY 25, 2004 APPROVED BY STOCKHOLDERS ON MAY 5, 2004 AMENDED BY THE BOARD OF DIRECTORS ON APPROVED BY STOCKHOLDERS ON (a) The purpose of the Plan is to provide a means by which Employees of
Read more →ACADACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results
ACADIA Pharmaceuticals Reports First Quarter 2016 Financial Results SAN DIEGO, CA May 5, 2016 - ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in cen
Read more →ACADFDA Approves ACADIA Pharmaceuticals NUPLAZID (pimavanserin) - The First Drug Approved for the Treatment of Hallucinations and Delusions Associated with Parkinson s Disease Psychosis U.S. Commercial Launch Planned for Jun
FDA Approves ACADIA Pharmaceuticals NUPLAZID (pimavanserin) - The First Drug Approved for the Treatment of Hallucinations and Delusions Associated with Parkinson s Disease Psychosis U.S. Commercial Launch Planned for June 2016 An Estimated 40 Percent of Parkinson s Disease Pa
Read more →ACADACADIA Pharmaceuticals Inc. Description of Executive Officer Annual Incentive Cash Compensation Program The Compensation Committee (the Committee ) of the Board of Directors (the Board ) of ACADIA Pharmaceuticals Inc. (t
ACADIA Pharmaceuticals Inc. Description of Executive Officer Annual Incentive Cash Compensation Program The Compensation Committee (the Committee ) of the Board of Directors (the Board ) of ACADIA Pharmaceuticals Inc. (the Company ) has recommended to the Board, and the Board h
Read more →ACADACADIA Pharmaceuticals Inc. Lisa Barthelemy, Senior Director, Investor Relations (858) 558-2871 ACADIA PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2015
ACADIA Pharmaceuticals Inc. Lisa Barthelemy, Senior Director, Investor Relations ACADIA PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2015 SAN DIEGO, CA February 29, 2016 ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmace
Read more →ACADCOMPANY OVERVIEW Company Overview We are a biopharmaceutical company focused on the development and commercialization of innovative small molecule drugs that address unmet medical needs in central nervous system disorder
We are a biopharmaceutical company focused on the development and commercialization of innovative small molecule drugs that address unmet medical needs in central nervous system disorders. We have a portfolio of product opportunities led by our novel drug candidate, NUPLAZIDTM (
Read more →ACADACADIA Pharmaceuticals Inc. Management Severance Benefit Plan Section 1. Introduction. The ACADIA Pharmaceuticals Inc. Management Severance Benefit Plan (the " Plan ") is hereby established effective
ACADIA Pharmaceuticals Inc. Management Severance Benefit Plan Section 1. Introduction. The ACADIA Pharmaceuticals Inc. Management Severance Benefit Plan (the "Plan") is hereby established effective December 10, 2015 (the "Effective Date"). The purpose of the Plan is to provide
Read more →ACADACADIA Pharmaceuticals Inc. Lisa Barthelemy, Director of Investor Relations (858) 558-2871 ACADIA PHARMACEUTICALS REPORTS THIRD QUARTER 2015
ACADIA Pharmaceuticals Inc. Lisa Barthelemy, Director of Investor Relations ACADIA PHARMACEUTICALS REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS SAN DIEGO, CA November 5, 2015 - ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development
Read more →ACADEMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the Agreement ) is made and entered into effective as of
EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the Agreement ) is made and entered into effective as of September 1, 2015 (the Effective Date ) by and between ACADIA Pharmaceuticals Inc., a Delaware Corporation (the Company ), and Stephen R. Davi
Read more →ACADACADIA Pharmaceuticals Inc. Steve Davis, Interim Chief Executive Officer Lisa Barthelemy, Director of Investor Relations (858) 558-2871 ACADIA PHARMACEUTICALS REPORTS SECOND QUARTER 2015
ACADIA Pharmaceuticals Inc. Steve Davis, Interim Chief Executive Officer Lisa Barthelemy, Director of Investor Relations ACADIA PHARMACEUTICALS REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS SAN DIEGO, CA August 6, 2015 - ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharm
Read more →ACADACADIA Pharmaceuticals Inc. Steve Davis, Interim Chief Executive Officer Lisa Barthelemy, Director of Investor Relations (858) 558-2871 ACADIA PHARMACEUTICALS REPORTS FIRST QUARTER 2015
ACADIA Pharmaceuticals Inc. Steve Davis, Interim Chief Executive Officer Lisa Barthelemy, Director of Investor Relations ACADIA PHARMACEUTICALS REPORTS FIRST QUARTER 2015 FINANCIAL RESULTS SAN DIEGO, CA May 7, 2015 - ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceu
Read more →ACADInvestor Contacts: ACADIA Pharmaceuticals Inc. Steve Davis, Interim Chief Executive Officer Lisa Barthelemy, Director of Investor Relations (858) 558-2871 Media Contact: Russo Partners David Schull (858) 717-2310 david.s
ACADIA Pharmaceuticals Inc. Steve Davis, Interim Chief Executive Officer Lisa Barthelemy, Director of Investor Relations david.schull@russopartnersllc.com ACADIA PHARMACEUTICALS ANNOUNCES RETIREMENT OF ULI HACKSELL, PH.D., CHIEF EXECUTIVE OFFICER Steve Davis Appointed Inter
Read more →ACADACADIA Pharmaceuticals Inc. Steve Davis, Executive Vice President, Chief Financial Officer and Chief Business Officer Lisa Barthelemy, Director of Investor Relations (858) 558-2871 ACADIA PHARMACEUTICALS REPORT
ACADIA Pharmaceuticals Inc. Steve Davis, Executive Vice President, Chief Financial Officer and Chief Business Officer Lisa Barthelemy, Director of Investor Relations ACADIA PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2014 SAN
Read more →ACADInvestor Contacts: ACADIA Pharmaceuticals Inc. Steve Davis, Executive Vice President, Chief Financial Officer and Chief Business Officer Lisa Barthelemy, Director of Investor Relations (858) 558-2871 Media Contact: Russo
ACADIA PHARMACEUTICALS REPORTS THIRD QUARTER 2014 FINANCIAL RESULTS AND UPDATES TIMING OF NUPLAZID NDA SUBMISSION SAN DIEGO, CA November 10, 2014 - ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innova
Read more →ACADSecconnect.com Investor Contacts: ACADIA Pharmaceuticals Inc. Uli Hacksell, Ph.D., Chief Executive Officer Lisa Barthelemy, Director of Investor Relations (858) 558-2871 Media Contact: Chandler Chicco Companies David Pol
ACADIA Pharmaceuticals Inc. Uli Hacksell, Ph.D., Chief Executive Officer Lisa Barthelemy, Director of Investor Relations Chandler Chicco Companies (310) 309-1029 or (805) 428-5775 ACADIA PHARMACEUTICALS RECEIVES FDA BREAKTHROUGH THERAPY DESIGNATION FOR NUPLAZIDTM (PIMAVANSE
Read more →ACADACADIA Pharmaceuticals Inc. Uli Hacksell, Ph.D., Chief Executive Officer Lisa Barthelemy, Director of Investor Relations (858) 558-2871 ACADIA PHARMACEUTICALS REPORTS FIRST QUARTER 2014
ACADIA Pharmaceuticals Inc. Uli Hacksell, Ph.D., Chief Executive Officer Lisa Barthelemy, Director of Investor Relations ACADIA PHARMACEUTICALS REPORTS FIRST QUARTER 2014 FINANCIAL RESULTS SAN DIEGO, CA May 6, 2014 - ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceu
Read more →ACADACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer Lisa Barthelemy, Director of Investor Relations (858) 558-2871 ACADIA PHARMACEUTICALS RE
ACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer Lisa Barthelemy, Director of Investor Relations ACADIA PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2013
Read more →ACADACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer Lisa Barthelemy, Director, Investor Relations (858) 558-2871 ACADIA PHARMACEUTICALS REPO
ACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer Lisa Barthelemy, Director, Investor Relations ACADIA PHARMACEUTICALS REPORTS SECOND QUARTER 2013 FINANCIAL RESULTS SAN DIEGO, CA August 6, 2013 - ACADIA
Read more →ACADLEASE 11085 TORREYANA ROAD HCP TORREYANA, LLC, a Delaware limited liability company, as Landlord, and ACADIA PHARMACEUTICALS INC., a Delaware corporation, as Tenant. TABLE OF CONTENTS Page 1. PREMISES, BUILDING, PROJECT,
11085 TORREYANA ROAD LLC, a Delaware limited liability company, ACADIA PHARMACEUTICALS INC., a Delaware corporation, Page 1. PREMISES, BUILDING, PROJECT, AND COMMON AREAS 7 2. LEASE TERM; OPTION TERM 9 3. BASE RENT 11 4. ADDITIONAL RENT 12 5. USE OF PREM
Read more →ACADText Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. AMENDMENT TO 1999 COLLABORATIVE RESEARCH, DEVELOPMENT A
***Text Omitted and Filed Separately with the Securities and Exchange Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) 1999 COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT THIS AMENDMENT TO 1999 COLLABORATIVE RESEARCH, DEVELOPMENT AND LICENS
Read more →ACADACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer Lisa Barthelemy, Director of Investor Relations (858) 558-2871
ACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer Lisa Barthelemy, Director of Investor Relations ACADIA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK SAN DIEGO, CA May 14, 2013 ACAD
Read more →ACADACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer (858) 558-2871 ACADIA PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AN
ACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer ACADIA PHARMACEUTICALS REPORTS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2012 SAN DIEGO, CA March 12, 2013 - ACADIA Pharmaceuti
Read more →ACADACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer (858) 558-2871 ACADIA PHARMACEUTICALS ANNOUNCES $86 MILLION EQUITY FINANCING Proceeds to
ACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer ACADIA PHARMACEUTICALS ANNOUNCES $86 MILLION EQUITY Proceeds to Support Completion of Pimavanserin Phase III Program SAN DIEGO, CA December 12, 2012 ACAD
Read more →ACADSECURITIES PURCHASE AGREEMENT This S ECURITIES P URCHASE A GREEMENT (this Agreement ), dated as of
SECURITIES PURCHASE AGREEMENT PURCHASE AGREEMENT (this Agreement ), dated as of December 12, 2012, is made by and among ACADIA PHARMACEUTICALS INC., a Delaware corporation (the Company ), and the Purchasers listed on Exhibit A hereto, together with their permitted transferees (
Read more →ACADInvestor Contacts: ACADIA Pharmaceuticals Inc. Uli Hacksell, Ph.D., Chief Executive Officer Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer (858) 558-2871 Media Contact: Russ
ACADIA Pharmaceuticals Inc. Uli Hacksell, Ph.D., Chief Executive Officer Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer (212) 845-4271 or (858) 717-2310 david.schull@russopartnersllc.com ACADIA ANNOUNCES PIMAVANSERIN MEETS PRIM
Read more →ACADACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer (858) 558-2871 ACADIA PHARMACEUTICALS REPORTS THIRD QUARTER 2012
ACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer ACADIA PHARMACEUTICALS REPORTS THIRD QUARTER 2012 FINANCIAL RESULTS SAN DIEGO, CA November 5, 2012 - ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopha
Read more →ACADACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer (858) 558-2871 ACADIA PHARMACEUTICALS REPORTS SECOND QUARTER 2012
ACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer ACADIA PHARMACEUTICALS REPORTS SECOND QUARTER 2012 FINANCIAL RESULTS SAN DIEGO, CA August 8, 2012 - ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biophar
Read more →ACADACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer (858) 558-2871 ACADIA PHARMACEUTICALS REPORTS FIRST QUARTER 2012
ACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer ACADIA PHARMACEUTICALS REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS SAN DIEGO, CA May 8, 2012 - ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmace
Read more →ACADAT-THE-MARKET ISSUANCE SALES AGREEMENT, DATED MARCH 30, 2012, BY AND BETWEEN ACADIA PHARMACEUTICALS INC. AND MLV & CO. LLC ex99-1.htm EX 99.1 ACADIA PHARMACEUTICALS INC. Common Stock (par value $0.0001 per share) At-The-
ACADIA PHARMACEUTICALS INC. (par value $0.0001 per share) At-The-Market Issuance Sales Agreement 1251 Avenue of the Americas Ladies and Gentlemen: ACADIA Pharmaceuticals Inc., a Delaware corporation (the "Company"), confirms its agreement (this "Agreement") with MLV & Co. LL
Read more →ACADSecconnect.com Contact: ACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer (858) 558-2871 ACADIA PHARMACEUTICALS REPORTS THIRD QUARTER 2011
ACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer ACADIA PHARMACEUTICALS REPORTS THIRD QUARTER 2011 FINANCIAL RESULTS SAN DIEGO, CA November 9, 2011 ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharm
Read more →ACADACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer (858) 558-2871 ACADIA PHARMACEUTICALS REPORTS SECOND QUARTER 2011
ACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer ACADIA PHARMACEUTICALS REPORTS SECOND QUARTER 2011 FINANCIAL RESULTS SAN DIEGO, CA August 10, 2011 - ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopha
Read more →ACADACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer (858) 558-2871 ACADIA PHARMACEUTICALS REPORTS FIRST QUARTER 2011
ACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer ACADIA PHARMACEUTICALS REPORTS FIRST QUARTER 2011 FINANCIAL RESULTS SAN DIEGO, CA May 10, 2011 ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceu
Read more →ACADACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer (858) 558-2871 ACADIA PHARMACEUTICALS REPORTS THIRD QUARTER 2010
Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer ACADIA PHARMACEUTICALS REPORTS THIRD QUARTER 2010 FINANCIAL RESULTS SAN DIEGO, CA November 9, 2010 ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceuti
Read more →ACADAMENDMENT NO. 1 TO COMMON STOCK PURCHASE AGREEMENT This Amendment No. 1 to the Common Stock Purchase Agreement, dated as of
COMMON STOCK PURCHASE AGREEMENT This Amendment No. 1 to the Common Stock Purchase Agreement, dated as of September 21, 2010 (this Amendment ), to the Common Stock Purchase Agreement dated as of August 4, 2008 (the Purchase Agreement ) is entered into by and between ACADIA Pharm
Read more →ACADACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer (858) 558-2871 ACADIA PHARMACEUTICALS REPORTS SECOND QUARTER 2010
ACADIA Pharmaceuticals Inc. Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer PHARMACEUTICALS REPORTS SECOND QUARTER 2010 FINANCIAL RESULTS SAN DIEGO, CA August 9, 2010 ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutica
Read more →Competitive Position
How ACAD ranks across every disease it competes inCompetitive Position is a premium feature
See how ACAD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial